“According to a new report published by Introspective Market Research, titled, Biobanking Market by Product & Service, Sample Type, and End User, The Global Biobanking Market Size Was Valued at USD 56.40 Billion in 2024 and is Projected to Reach USD 88.68 Billion by 2035, Growing at a CAGR of 4.2% from 2025–2035.”
The biobanking market plays a critical role in modern biomedical research by enabling the systematic collection, processing, storage, and distribution of biological samples such as blood, tissue, DNA, RNA, and other biospecimens. These samples are essential for advancing research in genomics, personalized medicine, drug discovery, and disease diagnostics. Biobanks provide standardized, high-quality samples that improve research reproducibility and accelerate translational outcomes.
Compared to traditional sample storage methods, biobanking solutions offer enhanced data integrity, long-term preservation, traceability, and compliance with regulatory and ethical standards. The integration of automated storage systems, digital sample tracking, and advanced cryopreservation technologies has further improved operational efficiency and sample viability.
Biobanking is widely used across pharmaceutical and biotechnology companies, academic and research institutes, and hospitals for clinical research, population studies, and precision medicine initiatives. Growing investments in life sciences research and increasing focus on personalized healthcare are positioning biobanking as a foundational infrastructure for future medical advancements.
Market Segmentation
The Biobanking Market is segmented into Product & Service, Sample Type, and End User.
- By Product & Service, the market is categorized into Equipment, Consumables, and Services.
- By Sample Type, the market is categorized into Blood Products, Human Tissues, Nucleic Acids, Cell Lines, and Others.
- By End User, the market is categorized into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Hospitals.
Growth Driver
One of the primary growth drivers of the biobanking market is the rapid expansion of precision and personalized medicine. Increasing understanding of genetic and molecular variability among patients has driven demand for high-quality biospecimens linked with clinical data. Biobanks support large-scale genomic and biomarker studies that enable targeted therapies and improved patient outcomes. Additionally, rising prevalence of chronic diseases and cancer is accelerating clinical research activities, thereby increasing reliance on biobanking infrastructure to support long-term and multicenter studies.
Market Opportunity
A key opportunity in the biobanking market lies in the integration of digital technologies such as artificial intelligence, big data analytics, and cloud-based biobank management systems. These technologies enhance sample utilization, data interoperability, and predictive research capabilities. Emerging economies are also presenting significant growth opportunities due to increasing healthcare investments, expanding research ecosystems, and government-supported population biobanking initiatives. Strategic collaborations between biobanks, pharmaceutical companies, and research institutions are expected to further unlock market potential.
Detailed Segmentation
Biobanking Market, Segmentation
The Biobanking Market is segmented on the basis of Product & Service, Sample Type, and End User.
Product & Service
The Product & Service segment is further classified into Equipment, Consumables, and Services. Among these, the Equipment sub-segment accounted for the highest market share in 2024. Biobanking equipment, including freezers, cryogenic storage systems, and automated sample handling solutions, forms the backbone of biobank operations. Continuous advancements in temperature-controlled storage, automation, and monitoring systems are driving strong demand for equipment to ensure sample integrity and regulatory compliance.
Sample Type
The Sample Type segment is further classified into Blood Products, Human Tissues, Nucleic Acids, and Cell Lines. Among these, the Blood Products sub-segment accounted for the highest market share in 2024. Blood-based samples are extensively used in clinical diagnostics, biomarker discovery, and epidemiological studies. Their ease of collection, broad applicability, and compatibility with multiple analytical techniques make blood products the most widely stored and utilized biospecimens in biobanks globally.
Some of The Leading/Active Market Players Are-
• Thermo Fisher Scientific (US)
• QIAGEN (Germany)
• Merck KGaA (Germany)
• BD (US)
• Hamilton Company (US)
• Brooks Automation (US)
• Tecan Group (Switzerland)
• Azenta Life Sciences (US)
• Chart Industries (US)
• Greiner Bio-One (Austria)
• STEMCELL Technologies (Canada)
• LabVantage Solutions (US)
and other active players.
Key Industry Developments
In March 2024, a leading life sciences company expanded its biobanking services portfolio to support large-scale genomic research initiatives.
The expansion included advanced cryogenic storage facilities and digital sample management platforms, enabling researchers to securely store and analyze millions of biospecimens while ensuring compliance with global regulatory standards.
In October 2024, a major academic biobank announced a strategic collaboration with pharmaceutical companies to accelerate oncology research.
The partnership focuses on sharing high-quality cancer biospecimens and associated clinical data, aimed at speeding up biomarker discovery and development of targeted cancer therapies.
Key Findings of the Study
• Equipment and blood products are the dominant segments in the market
• North America leads due to strong research infrastructure
• Precision medicine is a key growth driver
• Automation and digital biobanking are major trends
